These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 23623928)
41. Promise of Immune Therapies in Multiple Myeloma. Anderson KC J Oncol Pract; 2018 Jul; 14(7):411-413. PubMed ID: 29996072 [No Abstract] [Full Text] [Related]
42. Autoimmuno-Anti-Tumor Immunity - Understanding the Immune Responses against "self" and "Altered-Self". Huang FP Front Immunol; 2014; 5():582. PubMed ID: 25452757 [No Abstract] [Full Text] [Related]
43. Immune responses in myeloma. LINTON AL; DUNNIGAN MG; THOMSON JA Br Med J; 1963 Jul; 2(5349):86-9. PubMed ID: 13930878 [No Abstract] [Full Text] [Related]
44. Mathematical analysis of the cellular immune reaction against tumour cells. De Weger RA; Dullens HF; De Boer RJ; Den Otter W Immunol Today; 1985 Nov; 6(11):316-7. PubMed ID: 25290993 [No Abstract] [Full Text] [Related]
45. Primary Immune Deficiencies - A rapidly emerging area of basic and clinical research. Singh S; Zhao X; Zhang H Genes Dis; 2020 Mar; 7(1):1-2. PubMed ID: 32181270 [No Abstract] [Full Text] [Related]
46. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. Sun J; Park C; Guenthner N; Gurley S; Zhang L; Lubben B; Adebayo O; Bash H; Chen Y; Maksimos M; Muz B; Azab AK J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35428704 [TBL] [Abstract][Full Text] [Related]
47. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. Shih CA; Chen WC World J Clin Cases; 2021 Jul; 9(21):5769-5781. PubMed ID: 34368296 [TBL] [Abstract][Full Text] [Related]
48. Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients. Zhaoyun L; Rong F Front Immunol; 2021; 12():663748. PubMed ID: 34290698 [TBL] [Abstract][Full Text] [Related]
49. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Nishida H Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072645 [TBL] [Abstract][Full Text] [Related]
50. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Zannella A; Marignani M; Begini P Viruses; 2019 Sep; 11(9):. PubMed ID: 31540124 [TBL] [Abstract][Full Text] [Related]
51. Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. Vela-Ojeda J; Esparza MAG; Majluf-Cruz A; García-Chavez J; Montiel-Cervantes LA; Reyes-Maldonado E; Hernandez-Caballero A; Rodríguez-González MG Int J Hematol; 2019 Sep; 110(3):306-312. PubMed ID: 31168767 [TBL] [Abstract][Full Text] [Related]
53. Hepatitis B in patients with hematological diseases: An update. Coluccio C; Begini P; Marzano A; Pellicelli A; Imperatrice B; Anania G; Delle Fave G; Marignani M World J Hepatol; 2017 Sep; 9(25):1043-1053. PubMed ID: 28951776 [TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109 [TBL] [Abstract][Full Text] [Related]
55. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883 [TBL] [Abstract][Full Text] [Related]
56. Insight to drug delivery aspects for colorectal cancer. Gulbake A; Jain A; Jain A; Jain A; Jain SK World J Gastroenterol; 2016 Jan; 22(2):582-99. PubMed ID: 26811609 [TBL] [Abstract][Full Text] [Related]
57. Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients. Pojero F; Casuccio A; Di Bassiano F; Gervasi F; Colonna Romano G; Caruso C Immun Ageing; 2015; 12():5. PubMed ID: 26101540 [TBL] [Abstract][Full Text] [Related]
58. Long-term disease control by pomalidomide-/dexamethasone-based therapy in a patient with advanced multiple myeloma: a case report and review of the literature. Danhof S; Schreder M; Strifler S; Einsele H; Knop S Case Rep Oncol; 2015; 8(1):189-95. PubMed ID: 25969681 [TBL] [Abstract][Full Text] [Related]
59. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Dosani T; Carlsten M; Maric I; Landgren O Blood Cancer J; 2015 Apr; 5(4):e306. PubMed ID: 25885426 [TBL] [Abstract][Full Text] [Related]